Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor: a secondary analysis of the DEEP Trial

Lam, Garrett; Hopoate-Sitake, Moana; Adair, Charles; Buckalew, Vardaman M.; Johnson, Donna; Lewis, David F.; Robinson, Christopher; Saade, George R.; Graves, Steven W.

doi:10.1016/j.ajog.2013.04.010

Cited by 22 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 Treatment with digoxin like fragment improves renal function in the early periods of preeclampsia. 36 However, in long term follow up, renal prognosis might be poor in previously preeclamptic women. Spaan et al also reported that creatinine clearance in 22 formerly preeclamptic women was lower after 23 years of follow up.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women

Tuzcu¹,

Aşıcıoğlu²,

Sünbül³

et al. 2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Section: Accepted Manuscriptmentioning

confidence: 99%

Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women

Tuzcu¹,

Aşıcıoğlu²,

Sünbül³

et al. 2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

“…Endogenous digitalis-like factors (EDLFs) are a family of circulating Na/Κ-ATPase inhibitors, including marinobufagenin, that are elevated in preeclampsia and contribute to its pathogenesis by mediating by guest on http://circres.ahajournals.org/ Downloaded from vasoconstriction and vascular fibrosis and inhibiting proliferation and invasion of the cytotrophoblast. [127][128][129][130] An antidigoxin antibody fragment (Digibind, Ovine Digoxin Immune Antibody) has been shown to attenuate the inhibitory effects of EDLFs on Na/Κ-ATPase, to lower BP in animal models of volume-dependent hypertension and to reduce maternal BP and preserve renal function in women with preeclampsia 131,132 (Table).…”

Section: Novel Approaches To Preeclampsia Treatmentmentioning

confidence: 99%

“…129,133 A secondary analysis of Digibond Efficacy Evaluation in Preeclampsia stratified participants by circulating levels of EDLF activity and found that the beneficial effects of Digibind on renal function and on utilization of antihypertensives, as well as some maternal and fetal/neonatal outcomes, were greater in women who were EDLF positive. 129 Digibind production was terminated by its manufacturer in 2010, and DigiFab, affinity purified Fab fragments of antidigoxin antibody, became the only antidigoxin antibody available for clinical use. 130 DigiFab has similar effects as Digibind on EDLFs derived from the blood of women with preeclampsia.…”

Section: Novel Approaches To Preeclampsia Treatmentmentioning

confidence: 99%

New Approaches in the Treatment of Hypertension

Oparil

Schmieder

2015

Circulation Research

236

137

View full text Add to dashboard Cite

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes. Despite a plethora of available treatment options, a substantial portion of the hypertensive population has uncontrolled blood pressure. The unmet need of controlling blood pressure in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. In this Compendium Review, we discuss new drugs and interventional treatments that are undergoing preclinical or clinical testing for hypertension treatment. New drug classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/III of development, while inhibitors of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na + /H + exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1–7)/Mas receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in phase I or preclinical development. The two main interventional approaches, transcatheter renal denervation and baroreflex activation therapy, are used in clinical practice for severe treatment resistant hypertension in some countries. Renal denervation is also being evaluated for treatment of various comorbidities, eg, chronic heart failure, cardiac arrhythmias and chronic renal failure. Novel interventional approaches in early development include carotid body ablation and arteriovenous fistula placement. Importantly, none of these novel drug or device treatments has been shown to prevent cardiovascular disease outcomes or death in hypertensive patients.

show abstract

“…Digibind was well tolerated, and results showed a reduction in decline in renal function and significantly improved NKA inhibition. Another exciting multi-centre, double-blind, placebo-controlled efficacy study of Digibind in pre-eclampsia (DEEP) has recently been concluded [79]. In women with severe pre-eclampsia who were remote from term and who were positive for CTS, the use of Digibind was associated with improved maternal and neonatal outcome.…”

Section: Cts and Disease Pathogenesismentioning

confidence: 99%

The Role of Cardiotonic Steroids in the Pathogenesis of Cardiomyopathy in Chronic Kidney Disease

Pavlović¹

2014

Nephron Clin Pract

View full text Add to dashboard Cite

Cardiotonic steroids (CTS) are a new class of hormones that circulate in the blood and are divided into two distinct groups, cardenolides, such as ouabain and digoxin, and bufadienolides, such as marinobufagenin, telocinobufagin and bufalin. They have the ability to bind and inhibit the ubiquitous transport enzyme sodium potassium pump, thus regulating intracellular Na⁺ concentration in every living cell. Although digoxin has been prescribed to heart failure patients for at least 200 years, the realization that CTS are endogenously produced has intensified research into their physiological and pathophysiological roles. Over the last two decades, substantial evidence has accumulated demonstrating the effects of endogenously synthesised CTS on the kidneys, vasculature and the heart. In this review, the current state of art and the controversies surrounding the manner in which CTS mediate their pathophysiological effects are discussed. Several potential therapeutic strategies have emerged as a result of our increased understanding of the role CTS play in health and disease.

show abstract

Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor: a secondary analysis of the DEEP Trial

Cited by 22 publications

References 26 publications

Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women

Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women

New Approaches in the Treatment of Hypertension

The Role of Cardiotonic Steroids in the Pathogenesis of Cardiomyopathy in Chronic Kidney Disease

Contact Info

Product

Resources

About